| scholarly article | Q13442814 |
| P356 | DOI | 10.1111/JDV.12172 |
| P698 | PubMed publication ID | 23611501 |
| P50 | author | Valeria Brazzelli | Q57029362 |
| Giovanni Borroni | Q57529094 | ||
| P2093 | author name string | V Grasso | |
| P2860 | cites work | AMN107 (nilotinib): a novel and selective inhibitor of BCR-ABL | Q24651465 |
| Cell signaling by receptor tyrosine kinases | Q27860474 | ||
| The role of Kit-ligand in melanocyte development and epidermal homeostasis | Q28204716 | ||
| Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias | Q28246193 | ||
| Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL | Q28246204 | ||
| Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia | Q29547900 | ||
| Overriding imatinib resistance with a novel ABL kinase inhibitor | Q30014844 | ||
| Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance | Q33376325 | ||
| Dasatinib: a review of its use in the treatment of chronic myeloid leukaemia and Philadelphia chromosome-positive acute lymphoblastic leukaemia. | Q33397085 | ||
| Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION). | Q33398716 | ||
| Review: Melanocyte Migration and Survival Controlled by SCF/c-kit Expression | Q34107031 | ||
| Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia | Q34183674 | ||
| Role of tyrosine kinase inhibitors in cancer therapy | Q34432091 | ||
| Tyrosine kinase inhibitors - a review on pharmacology, metabolism and side effects | Q34610898 | ||
| Practical management of patients with chronic myeloid leukemia receiving imatinib | Q35095956 | ||
| Platelet-derived growth factor beta receptor regulates interstitial fluid homeostasis through phosphatidylinositol-3' kinase signaling | Q35649971 | ||
| Pityriasis rosea-like Drug Eruption Induced by Imatinib Mesylate (Gleevec™) | Q35748794 | ||
| Indications for imatinib mesylate therapy and clinical management | Q35787974 | ||
| Cutaneous side-effects of kinase inhibitors and blocking antibodies | Q36181698 | ||
| Tyrosine kinase inhibitors for the treatment of Philadelphia chromosome-positive adult acute lymphoblastic leukemia | Q36911647 | ||
| Dasatinib and chronic myeloid leukemia: two-year follow-up in eight clinical trials | Q37642276 | ||
| Lichenoid drug eruption with palmoplantar hyperkeratosis due to imatinib mesylate: a case report and a review of the literature. | Q37682628 | ||
| Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia resistant to imatinib at a dose of 400 to 600 milligrams daily: two-year follow-up of a randomized phase 2 study (START-R). | Q37692798 | ||
| Practical management of tyrosine kinase inhibitor-associated side effects in GIST. | Q37767003 | ||
| Adverse cutaneous reactions secondary to tyrosine kinase inhibitors including imatinib mesylate, nilotinib, and dasatinib. | Q37930709 | ||
| Tyrosine kinase inhibitors and drug interactions: a review with practical recommendations | Q37981002 | ||
| Rash with the multitargeted kinase inhibitors nilotinib and dasatinib: meta-analysis and clinical characterization | Q38067464 | ||
| In vitro evaluation of photosensitivity risk related to genetic polymorphisms of human ABC transporter ABCG2 and inhibition by drugs | Q40030959 | ||
| Sweet's syndrome with CML cell infiltration of the skin in a patient with chronic-phase CML while taking Imatinib Mesylate | Q40537720 | ||
| Oral lichenoid reaction to imatinib (STI 571, Gleevec). | Q40635394 | ||
| Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial | Q42613611 | ||
| Nilotinib is superior to imatinib as first-line therapy of chronic myeloid leukemia: the ENESTnd study. | Q42796997 | ||
| Imatinib mesylate-induced pseudoporphyria | Q43028105 | ||
| Cutaneous reactions to STI571. | Q43723840 | ||
| Acute generalized exanthematous pustulosis associated with STI571 in a patient with chronic myeloid leukemia | Q43732601 | ||
| Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia | Q43899710 | ||
| Stevens-Johnson syndrome after treatment with STI571: a case report | Q44004546 | ||
| Imatinib mesylate and gray hair | Q44094545 | ||
| Pityriasis rosea associated with imatinib (STI571, Gleevec). | Q44129568 | ||
| Sti571-induced Stevens-Johnson Syndrome | Q44163529 | ||
| Managing cutaneous reactions to imatinib therapy | Q44202316 | ||
| Imatinib-induced acute generalized exanthematous pustulosis (AGEP) in two patients with chronic myeloid leukemia | Q44216050 | ||
| Adverse cutaneous reactions to imatinib (STI571) in Philadelphia chromosome-positive leukemias: a prospective study of 54 patients | Q44312442 | ||
| Severe skin reaction to imatinib in a case of Philadelphia-positive acute lymphoblastic leukemia. | Q44333229 | ||
| A spectrum of skin reactions caused by the tyrosine kinase inhibitor imatinib mesylate (STI 571, Glivec). | Q44339633 | ||
| Photosensitization in chronic myelogenous leukaemia patients treated with imatinib mesylate | Q44369418 | ||
| Squamous cutaneous epithelial cell carcinoma in two CML patients with progressive disease under imatinib treatment | Q44375760 | ||
| Mycosis fungoides-like reaction in a patient treated with Gleevec | Q44393917 | ||
| Reactivation of porphyria cutanea tarda as a possible side effect of Imatinib at high dosage in chronic myeloid leukemia | Q44628909 | ||
| Disseminated Erythematous and Pityriasiform Plaques Caused by Imatinib Mesylate | Q44649706 | ||
| EBV-positive cutaneous B-cell lymphoproliferative disease after imatinib mesylate | Q44659613 | ||
| Imatinib mesylate causes hypopigmentation in the skin | Q44667131 | ||
| Pigmentary changes in chronic myeloid leukemia patients treated with imatinib mesylate | Q44754104 | ||
| Lichenoid cutaneous reaction to imatinib | Q45023013 | ||
| Adverse reactions during imatinib and lansoprazole treatment in gastrointestinal stromal tumors | Q45152647 | ||
| Follicular mucinosis associated with imatinib (STI571). | Q45192166 | ||
| Neutrophilic eccrine hidradenitis induced by imatinib mesylate (Gleevec) therapy | Q45192946 | ||
| Early and tardive skin adverse events in chronic myeloid leukaemia patients treated with imatinib | Q45227567 | ||
| Imatinib: a designer drug, another cutaneous complication. | Q45987921 | ||
| Stevens-Johnson syndrome induced by combination of imatinib and allopurinol. | Q46013718 | ||
| The toxicities of modern targeted therapies: learning from the price of progress | Q46055666 | ||
| Skin and oral lesions associated to imatinib mesylate therapy | Q46225988 | ||
| Imatinib-induced hand-foot syndrome in a patient with metastatic gastrointestinal stromal tumor | Q46308279 | ||
| Oral lichenoid eruption secondary to imatinib (Glivec). | Q46374694 | ||
| Imatinib-induced sweet syndrome in a patient with chronic myeloid leukemia | Q46395749 | ||
| Bullous sweet syndrome in a patient with t(9;22)(q34;q11)-positive chronic myeloid leukemia treated with the tyrosine kinase inhibitor nilotinib: interphase cytogenetic detection of BCR-ABL- positive lesional cells | Q46696380 | ||
| Pityriasis rosea-like eruption during treatment with imatinib mesylate: description of 3 cases | Q46755036 | ||
| Severe pustular eruption associated with imatinib and voriconazole in a patient with chronic myeloid leukemia | Q46802936 | ||
| Lichenoid eruption due to imatinib | Q46880437 | ||
| Imatinib induced Stevens-Johnson syndrome: lack of recurrence following re-challenge with a lower dose | Q46880442 | ||
| The SCF/KIT Pathway Plays a Critical Role in the Control of Normal Human Melanocyte Homeostasis | Q47704015 | ||
| Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up. | Q54504324 | ||
| Topical psoralen plus UV-A therapy for tyrosine kinase inhibitor-induced hand-foot syndrome. | Q54516932 | ||
| Hair depigmentation and vitiligo-like lesions in a leukaemic paediatric patient during chemotherapy with dasatinib. | Q54531810 | ||
| Photoinduced dermatitis and oral lichenoid reaction in a chronic myeloid leukemia patient treated with imatinib mesylate. | Q54539108 | ||
| Panniculitis during Dasatinib Therapy for Imatinib-Resistant Chronic Myelogenous Leukemia | Q57748971 | ||
| Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy | Q58023949 | ||
| Dasatinib-related alveolar pneumonia responsive to corticosteroids | Q58376547 | ||
| MAP kinase links the transcription factor Microphthalmia to c-Kit signalling in melanocytes | Q59096765 | ||
| P433 | issue | 12 | |
| P921 | main subject | imatinib | Q177094 |
| dasatinib | Q419940 | ||
| dasatinib monohydrate | Q27139135 | ||
| P304 | page(s) | 1471-1480 | |
| P577 | publication date | 2013-04-24 | |
| P1433 | published in | Journal of the European Academy of Dermatology and Venereology | Q15760872 |
| P1476 | title | Imatinib, dasatinib and nilotinib: a review of adverse cutaneous reactions with emphasis on our clinical experience | |
| P478 | volume | 27 |
| Q42756487 | A newborn with teratogenic effect of imatinib mesylate: a very rare case report |
| Q38852257 | C-kit mutations determine dasatinib mechanism of action in HMC-1 neoplastic mast cells: dasatinib differently regulates PKCδ translocation in HMC-1(560) and HMC-1(560,816) cell lines |
| Q38189112 | Drug-induced photoallergic and phototoxic reactions - an update |
| Q38370667 | Erythema nodosum-like lesions during BRAF inhibitor therapy: Report on 16 new cases and review of the literature |
| Q26749324 | European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia |
| Q54345379 | Imatinib mesylate-induced pseudoporphyria in two children |
| Q47561716 | Long-term mucocutaneous adverse effects of imatinib in Indian chronic myeloid leukemia patients |
| Q59640070 | Management of Adverse Events Associated with ATP-Competitive BCR-ABL1 Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia |
| Q38392679 | Management of adverse events associated with tyrosine kinase inhibitors in chronic myeloid leukemia |
| Q54327179 | Multiple squamous cell carcinomas following introduction of nilotinib |
| Q50213000 | Nilotinib-induced panniculitis in a patient with chronic myelogenous leukaemia |
| Q53709484 | Ponatinib-induced widespread ichthyosiform eruption |
| Q38246305 | Tyrosine kinase inhibitors as reversal agents for ABC transporter mediated drug resistance. |
| Q30577227 | Vinculin phosphorylation differentially regulates mechanotransduction at cell-cell and cell-matrix adhesions |
| Q55032171 | Xanthelasma palpebrarum: a new side effect of nilotinib. |
Search more.